List view / Grid view
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
4 September 2013 | By AstraZeneca
As a result of the initiation of this programme, a pre-tax impairment charge of $285 million will be reversed and the asset restored to our balance sheet in the third quarter of 2013...
2 September 2013 | By AstraZeneca
SAVOR provides information on cardiovascular safety for Onglyza in the wake of past questions about cardiovascular safety of type 2 diabetes treatments...
28 August 2013 | By Carbon Trust
ABPI collaborates with the Carbon Trust to help pharmaceutical companies quickly estimate the carbon footprint of tablet medicines distributed in blister packs...
26 August 2013 | By AstraZeneca
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune...
6 August 2013 | By Financial Times
3 – 4 December 2013, The InterContinental Park Lane, London...
31 July 2013 | By AstraZeneca
Collaboration to include US, China and selected other markets...
25 July 2013 | By AstraZeneca
The US FDA has acknowledged receipt of the NDA resubmission for investigational drug dapagliflozin for the treatment of adults with type 2 diabetes...
25 July 2013 | By AstraZeneca
NDA for dapagliflozin resubmitted to FDA...
15 July 2013 | By AstraZeneca
AstraZeneca announced that Simon Lowth, CFO and Executive Director, will leave the company at the end of October...
9 July 2013 | By AstraZeneca
AstraZeneca enters agreement with University of Cambridge & Cancer Research UK...
28 June 2013 | By AstraZeneca
AstraZeneca announced that on 27 June 2013 it completed its acquisition of Pearl Therapeutics...
19 June 2013 | By AstraZeneca
AstraZeneca and Bristol-Myers Squibb announced top-line results...
18 June 2013 | By AstraZeneca
"AstraZeneca’s investment is excellent news for the UK life sciences industry..."
17 June 2013 | By AstraZeneca
MedImmune and NGM Biopharmaceuticals have entered into an exclusive agreement...
13 June 2013 | By Payal Roychoudhury, formerly AstraZeneca and Ronan O’Kennedy, Fujifilm Diosynth Biotechologies and Jim Faulkner, GlaxoSmithKline and Brian McNeil & Linda M. Harvey, University of Strathclyde
Biopharmaceutical companies are constantly evaluating new methods for mammalian cell line development that offer benefits such as shorter time lines, improved consistency, higher monoclonal antibody (mAb) production, better genetic stability and increased flexibility. Each of these advantages extends a potentially large cost benefit to companies as their recombinant protein products…
